Switch theme
Sign up to access all valuation multiples
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.
1985
9.3K+
LTM Revenue $2.5B
LTM EBITDA $666M
$5.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aspen Pharmacare has a last 12-month revenue of $2.5B and a last 12-month EBITDA of $666M.
In the most recent fiscal year, Aspen Pharmacare achieved revenue of $2.4B and an EBITDA of $542M.
Aspen Pharmacare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aspen Pharmacare valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.2B | $2.4B | XXX | XXX | XXX |
| Gross Profit | $1.0B | $1.0B | XXX | XXX | XXX |
| Gross Margin | 45% | 41% | XXX | XXX | XXX |
| EBITDA | $528M | $542M | XXX | XXX | XXX |
| EBITDA Margin | 24% | 22% | XXX | XXX | XXX |
| Net Profit | $355M | $286M | XXX | XXX | XXX |
| Net Margin | 16% | 12% | XXX | XXX | XXX |
| Net Debt | $859M | $995M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Aspen Pharmacare's stock price is ZAR 157 (or $9).
Aspen Pharmacare has current market cap of ZAR 69.9B (or $3.8B), and EV of ZAR 98.5B (or $5.4B).
See Aspen Pharmacare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.4B | $3.8B | XXX | XXX | XXX | XXX | $0.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Aspen Pharmacare has market cap of $3.8B and EV of $5.4B.
Aspen Pharmacare's trades at 2.1x LTM EV/Revenue multiple, and 8.1x LTM EBITDA.
Analysts estimate Aspen Pharmacare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aspen Pharmacare and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.4B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.8x | XXX | XXX | XXX |
| P/E | 13.1x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | 61.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAspen Pharmacare's NTM/LTM revenue growth is 10%
Aspen Pharmacare's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Aspen Pharmacare's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aspen Pharmacare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aspen Pharmacare and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 34% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aspen Pharmacare acquired XXX companies to date.
Last acquisition by Aspen Pharmacare was XXXXXXXX, XXXXX XXXXX XXXXXX . Aspen Pharmacare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aspen Pharmacare founded? | Aspen Pharmacare was founded in 1985. |
| Where is Aspen Pharmacare headquartered? | Aspen Pharmacare is headquartered in South Africa. |
| How many employees does Aspen Pharmacare have? | As of today, Aspen Pharmacare has 9.3K+ employees. |
| Who is the CEO of Aspen Pharmacare? | Aspen Pharmacare's CEO is Mr. Stephen Saad. |
| Is Aspen Pharmacare publicy listed? | Yes, Aspen Pharmacare is a public company listed on JSE. |
| What is the stock symbol of Aspen Pharmacare? | Aspen Pharmacare trades under APN ticker. |
| When did Aspen Pharmacare go public? | Aspen Pharmacare went public in 1990. |
| Who are competitors of Aspen Pharmacare? | Similar companies to Aspen Pharmacare include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Aspen Pharmacare? | Aspen Pharmacare's current market cap is $3.8B |
| What is the current revenue of Aspen Pharmacare? | Aspen Pharmacare's last 12-month revenue is $2.5B. |
| What is the current EBITDA of Aspen Pharmacare? | Aspen Pharmacare's last 12-month EBITDA is $666M. |
| What is the current EV/Revenue multiple of Aspen Pharmacare? | Current revenue multiple of Aspen Pharmacare is 2.1x. |
| What is the current EV/EBITDA multiple of Aspen Pharmacare? | Current EBITDA multiple of Aspen Pharmacare is 8.1x. |
| What is the current revenue growth of Aspen Pharmacare? | Aspen Pharmacare revenue growth between 2023 and 2024 was 10%. |
| Is Aspen Pharmacare profitable? | Yes, Aspen Pharmacare is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
